Although RAAS activation was not directly associated with OSA severity alone, these findings support refined management strategies for OSA patients, especially those with concurrent hypertension, and the potential benefits of mineralocorticoid receptor antagonists in controlling the BP and mitigating aldosterone-mediated effects in this population, particularly in tropical regions where metabolic disorders are increasingly prevalent. The gene discussed is NR3C2; the disease is Other metabolic disease.